|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT02433366 |
|
Date of registration:
|
25/03/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation
|
|
Scientific title:
|
Post-authorisation Study to Evaluate the Effectiveness of the Risk Minimisation Activities in the Treatment of SPAF |
|
Date of first enrolment:
|
January 2015 |
|
Target sample size:
|
1213 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02433366 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Bulgaria
|
Czech Republic
|
Denmark
|
France
|
Germany
|
Slovakia
|
Spain
|
United Kingdom
|
|
Contacts
|
|
Name:
|
Boehringer Ingelheim |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Boehringer Ingelheim |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
- Pradaxa® prescribers (cardiologists and primary care physicians)
- Patients with atrial fibrillation treated with Pradaxa®
Exclusion criteria:
As defined in Summary of Product Characteristics for patients treated with Pradaxa®
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Atrial Fibrillation
|
|
Primary Outcome(s)
|
|
Patient's Understanding of the Disease, Bleeding Signs, What to do in Case of Bleeding and How to Deal With Emergency Situations (Measuring Physician Compliance From Patient Perspective) (Questionnaire)
[Time Frame: Day 1]
|
|
Physician's Knowledge and Recommendations to Their Patients on Appropriate Dosing and Minimizing the Risk of Bleeding When Treated With Pradaxa® (Questionnaire)
[Time Frame: Day 1]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|